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The N-glycolylated ganglioside NeuGc-GM3 has been described in solid tumors such as breast carcinoma, nonsmall cell lung
cancer, and melanoma, but is usually not detected in normal human cells. Our aim was to evaluate the presence of NeuGc-GM3 in
pediatric neuroectodermal tumors by immunohistochemistry. Twenty-seven archival cases of neuroblastoma and Ewing sarcoma
family of tumors (ESFT) were analyzed. Formalin-ﬁxed, paraﬃn-embedded tumor samples were cut into 5µms e c t i o n s .T h e
monoclonal antibody 14F7, a mouse IgG1 that speciﬁcally recognizes NeuGc-GM3, and a peroxidase-labeled polymer conjugated
to secondary antibodies were used. Presence of NeuGc-GM3 was evident in 23 of 27 cases (85%), with an average of about 70% of
positive tumors cells. Immunoreactivity was moderate to intense in most tumors, showing a diﬀuse cytoplasmic and membranous
staining, although cases of ESFT demonstrated a ﬁne granular cytoplasmic pattern. No signiﬁcant diﬀerences were observed
between neuroblastoma with and without NMYC oncogene ampliﬁcation, suggesting that expression of NeuGc-GM3 is preserved
in more aggressive cancers. Until now, the expression of N-glycolylated gangliosides in pediatric neuroectodermal tumors has not
been investigated. The present study evidenced the expression of NeuGc-GM3 in a high proportion of neuroectodermal tumors,
suggesting its potential utility as a speciﬁc target of immunotherapy.
1.Introduction
Gangliosides are a broad family of glycosphingolipids found
on the outer cell membrane, initially suggested as potential
targets for cancer immunotherapy based on their higher
abundance in tumors when compared with the matched
normal tissues [1]. They are concentrated in the nervous
tissues, particularly in gray matter and synaptic junctions,
although they can also be detected in most cellular types in
much smaller quantities. Gangliosides are involved in cell
communication and also act as regulatory elements in the
immune system and in cancer progression [2, 3].
Neuroblastoma, a neoplasm originating from neural
crest cells, is the most common extracranial solid tumor
of childhood. Although it can arise from any site along
the sympathetic nervous system, primary tumors frequently
haveabdominalorthoraciclocation[4].Aberrantexpression
of NMYC oncogene plays a central role in neuroblastoma
tumorigenesis, and its ampliﬁcation is a major indicator
of high-risk cases [5]. Most patients achieve remission
with chemotherapy and surgery, but eradication of minimal
residual disease (MRD) remains the major challenge in
improving prognosis in high-risk neuroblastoma [4, 5].
The expression of a variety of gangliosides has been
described in detail in neuroblastoma for diagnostic purposes
andmorerecentlyfortherapeutictargeting,sincedisialogan-
glioside (GD2)-directed immunotherapy has been reported2 Clinical and Developmental Immunology
toimprovesurvivalinchildrenwithhigh-riskneuroblastoma
[6]. Anti-GD2 monoclonal antibodies, as well as newer
strategies such us immunocytokines and tumor vaccines, are
promising approaches to eliminate resistant neuroblastoma
cells [7].
The expression of N-glycolyl (NeuGc) gangliosides, and
particularly the monosialoganglioside NeuGc-GM3, in neu-
roblastoma has not been reported to our knowledge. These
gangliosides have recently received attention as a privileged
target for cancer immunotherapy based on results in adult
tumors [8]. Our group recently reported its expression in
pediatric Wilms tumor [9]. Since this ganglioside is not
detected in normal human cells, it may be considered as an
interesting neoantigen for cancer immunotherapy [8, 10].
The monoclonal antibody racotumomab (formerly
known as 1E10), an anti-idiotype vaccine that is able to
induce a speciﬁc response against NeuGc-containing gan-
gliosides, may be considered as an option for immunother-
apy in these children. Racotumomab showed promising
results in clinical trials in patients with advanced breast
carcinoma [11, 12], melanoma, [13], and nonsmall cell lung
cancer [14]. Furthermore, it was recently described that
induction in cancer patients of anti-NeuGc-GM3 antibodies
can cause tumor cell death by a complement-independent
oncosis-like mechanism [15].
Based on this experience, we aimed to investigate
the immunohistochemical expression of the N-glycolylated
ganglioside NeuGc-GM3 in neuroblastoma in order to
evaluate its potential as a target for immunotherapy. Cases of
Ewing sarcoma family of tumors (ESFTs) were also studied,
providing additional information in neuroectoderm-derived
pediatric cancers.
2.MaterialsandMethods
2.1. ArchivalCases. We retrospectively reviewedpathological
specimens from 27 patients with a diagnosis of neuroblas-
toma or ESFT treated at the Garrahan Pediatric Hospital
(Buenos Aires, Argentina). The median age of neuroblas-
toma patients was 22 months (range: 2 months to 11 years)
at initial diagnosis. The most frequent primary site was
abdominal, followed by thoracic, cervical, and axilar sites.
The median age of ESFT patients was 13 years (range: 9
to 14 years), with all cases being diagnosed as primary
extraosseous disease.
Neuroblastoma tumors were immunohistochemically
evaluated with the monoclonal antibody NB84 (Dako
Cytomation, Carpinteria, CA, USA) raised to neuroblastoma
cells, while cases of ESFT were examined using an anti-
CD99antibody(DakoCytomation).Additionalimmunohis-
tochemical markers were also assessed to conﬁrm the diag-
nosis of neuroblastoma or establish a diﬀerential diagnosis
with other small round blue cell tumors, including synap-
tophysin, neuroﬁlaments, neuron-speciﬁc enolase, Myf4,
terminal deoxynucleotide transferase, and vimentin. Patients
with high-risk neuroblastoma were treated with current
regimens based on evidence-based guidelines [16], thus they
underwent surgical removal of the primary tumor after
administration of 5 cycles of induction polychemotherapy.
Children with low-risk neuroblastoma were treated with
surgical resection only. Histological assessment and patho-
logical staging were in accordance with the International
Neuroblastoma Pathology Committe [17].
2.2. Fluorescent In Situ Hybridization (FISH). NMYC ampli-
ﬁcation was detected by FISH with a molecular speciﬁc DNA
probe for 2p24.1 (Vysis N-MYC, Spectrum Orange Probe,
Abbot Molecular, Abbot Park, IL, USA) on histological sec-
tions of neuroblastoma tumors. The number of ﬂuorescent
signals was evaluated in 200 intact, nonoverlapping nuclei of
tumor cells for each probe. Positive cases were considered
when the signals were of the same size and intensity.
Complementary, 1p deletion was checked in neuroblastoma
using a DNA probe for 1p36 (locus D1Z2). ESFT cases were
analyzed for the presence of t(11;22) translocation with a
probe for the EWR1 locus at 22q12.
2.3. Immunohistochemistry. The antiganglioside monoclonal
antibody 14F7 was provided by the Center of Molecular
Immunology (La Habana, Cuba) and used at a ﬁnal
concentration of 20µg/mL. The 14F7 antibody is a mouse
IgG1 that speciﬁcally recognizes the ganglioside NeuGc-
GM3, as previously described [12]. Sections of 5µmf r o m
formalin-ﬁxed, paraﬃn-embedded tumor samples were
used. After reaction of primary antibodies, sections were
incubated with a peroxidase-labeled polymer conjugated
to secondary anti-mouse antibodies using the EnVision+
System-HRP(DAB) (DakoCytomation) and developed with
3,3 -diaminobenzidine as chromogen. Proper positive and
negative controls were made in every staining battery.
Sections from breast carcinoma were employed as positive
controls of ganglioside detection [9]. We previously demon-
strated that the routine technique did not extract antigenic
carbohydrate determinants of gangliosides, thus allowing
immunohistochemical detection in tumor sections [18].
Detection of Ki-67 protein, a nuclear marker of proliferating
cells, was performed using the speciﬁc mouse monoclonal
antibody MIB-1 (DakoCytomation) at a dilution of 1:50.
2.4. Immunohistochemical Evaluation. NeuGc-GM3 expres-
sion was semiquantitatively evaluated, and results were
scored by three independent pathologists. In the rare event
of divergent evaluation, a consensus was found by discussing
the cases. We graded the intensity of the staining from 0
to 3:0 = no staining; 1+ = mild; 2+ = moderate; 3+ =
intense. Tumors were classiﬁed as negative when no staining
w a so b s e r v e do ro n l yl e s st h a n2 0 %o fc e l l sw e r ep o s i t i v e .
In addition, neuroblastoma tumors were assessed with the
immunoreactive score (IRS). The percentage of NeuGc-
GM3 positive cells was quantiﬁed in 5 high-power ﬁelds
(in average: 2,500 cells per case) and then scored in ﬁve
grades: 0 = 0–19%; 1 = 20–39%; 2 = 40–59%; 3 = 60–
79%; 4 = 80–100%. IRS was calculated for each specimen
by multiplication of the staining intensity and the grade of
positive cells, resulting in a score ranging from 0 to 12 as
described elsewhere [19].Clinical and Developmental Immunology 3
Table 1: NeuGc-GM3 immunopositivity in neuroectodermal pediatric tumors.
Tumor variant NeuGc-GM3
Positive casesa (%) Positive tumor cellsb (%) Predominant intensityc
Neuroblastoma, NMYC-ampliﬁed 9/11 (81) 66 ± 11.6 2+/3+
Neuroblastoma, NMYC-nonampliﬁed 9/11 (81) 69 ± 10.6 2+/3+
Ewing sarcoma family of tumors (ESFT) 5/5 (100) 71 ± 6.0 2+
Total 23/27 (85) 68 ± 6.3 2+
aPositive/total cases.
bValues are means ± SEM.
cIntensity of the positive staining was graded as 1+ = mild; 2+ = moderate; 3+ = intense.
2.5. Statistical Analysis. ANOVA followed Dunnett’s test was
used for multiple comparisons. Two groups were compared
using two-tailed unpaired Student’s test. Correlations were
analyzed using the Pearson’s test. A P value <0.05 was
considered statistically signiﬁcant. Table and bar graph
results are shown as mean ± standard error of the mean
(SEM).
3. Results
Presence of NeuGc-GM3 ganglioside was evident in 23
of 27 cases (85%) of neuroectodermal tumors (Table 1),
as detected by immunohistochemistry using the speciﬁc
monoclonal antibody 14F7. All cases of ESFT were positive,
w h e r e a ss o m en e g a t i v ec a s e so c c u r r e di nb o t hN M Y C -
ampliﬁed and -nonampliﬁed neuroblastoma. Absence of
NeuGc-GM3expressionwasnotassociatedwithanyparticu-
lartumorsiteorwiththeuseofpreoperativepolychemother-
apy in high-risk patients.
In average, about 70% of tumor cells were positive
for NeuGc-GM3 (see also Table 1). Immunoreactivity was
moderate to intense in most tumors, showing a diﬀuse
cytoplasmic and membranous staining in neuroblastoma
(Figure 1(a)),withoccasionalnuclearpositivityaspreviously
reported for lung tumors [20]. A ﬁne granular cytoplasmic
pattern was detected in cases of ESFT (Figure 1(b)). Inter-
estingly, most samples of neuroblastoma with an intense
NeuGc-GM3 staining corresponded to patients with an
age of less than 24 months. Adjacent adrenal tissue was
positive for NeuGc-GM3 in the cytoplasmic compartment in
some neuroblastoma cases analyzed, suggesting shedding of
gangliosides from cancer cells, as described in renal tumors
[9]. No expression of NeuGc-GM3 was detected in other
nontumoral tissue (Figure 1(d)).
All ESFT cases analyzed were positive for the t(11;22)
translocation by FISH. No signiﬁcant diﬀerences (P>0.05)
in NeuGc-GM3 expression were observed between NMYC-
ampliﬁed and -nonampliﬁed neuroblastoma, as assessed by
theIRS(Figure 2).Inthesameline,nosigniﬁcantcorrelation
was found between the percentage of cells positive for
the Ki-67 proliferating antigen and the NeuGc-GM3 IRS
(P>0.05; r = 0.1638). As expected, tumors with NMYC
ampliﬁcation demonstrated a signiﬁcantly higher expression
(P<0.02) of Ki-67 (see also Figure 2). Deletion of 1p36
was also conﬁrmed in association with NMYC ampliﬁcation
in these cases. Taken together, the present data suggest that
expression of NeuGc-GM3 is preserved in more aggressive
neuroectodermal cancers.
4. Discussion
To the best of our knowledge, this is the ﬁrst report on
the expression of N-glycolylated gangliosides in pediatric
neuroectodermal tumors. Our immunohistochemical study
usingaspeciﬁcmonoclonalantibodyevidencesNeuGc-GM3
expression in 85% of cases of neuroblastoma and ESFT. It
is known that complex glycosphingolipids are abundant in
cells of neuroectodermal origin [21], as well as in some
epithelial cells [22]. Mammalian cells are covered by a
dense glycocalyx, composed of glycolipids, glycoproteins,
glycophospholipid anchors, and proteoglycans. Sialic acids
attached to cell surface glycoconjugates play important roles
in many physiological and pathological processes, including
microbe binding that leads to infections, regulation of the
immune response, and progression and spread of human
malignancies [23]. The possibility that NeuGc-containing
glycoconjugates are taken up directly from diet must be
taken into account. However, the potential role of alternative
biosyntheticpathwaysofNeuGcinhumanneoplasia,includ-
ing pediatric tumors, is not known [24].
The most common sialic acids in mammals are N-acetyl
(NeuAc) and NeuGc neuraminic acids. The key step in
the biosynthesis of NeuGc is the conversion of NeuAc to
NeuGc, which is catalyzed by the cytidine monophospho-N-
acetylneuraminic acid hydroxylase [25]. NeuGc-containing
gangliosides are normal components of cell membranes in
all mammals except human beings. The lack of expression
of NeuGc in human tissues is due to inactivation by a
deletion of the hydrolase gene [26]. However, neosynthesis
of carbohydrate determinants and expression of NeuGc
gangliosides were observed in human cancer, possibly by
diet incorporation of nonhuman sialic acid from milk or
meat [10]. NeuGc-GM3 has been detected in prevalent
adult cancers such as nonsmall cell lung cancer [20], breast
carcinoma [27], and melanoma [28].
Ganglioside expression in ESFT has received little atten-
tion in the literature. The expression of GD2 has been
reported [29] but, to our knowledge, they have not been
widely used for immunotherapy [30]. Our preliminary
results may be used as background for potential devel-
opments in this area. Conversely, gangliosides have been4 Clinical and Developmental Immunology
(a) (b)
(c) (d)
Figure 1:ImmunohistochemicaldetectionofNeuGc-GM3 gangliosideinneuroectodermaltumors.(a)Neuroblastoma(NMYC-ampliﬁed).
(b) Ewing sarcoma family of tumors (ESFT). (c) Negative isotype control staining (mouse IgG1) in neuroblastoma. (d) No expression in
nontumoral neural tissue. Original magniﬁcation 400X (a, b and c), 100X (d), 1,000X (insets).
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Figure 2:ExpressionofNeuGc-GM3gangliosideandKi-67protein
in NMYC-ampliﬁed and -nonampliﬁed neuroblastoma. NeuGc-
GM3(openbars)wasassessedwiththeimmunoreactivescore(IRS)
and the percent of Ki-67 positive cells (closed bars) was used as a
proliferation index. Data represent mean ± SEM. ∗P<0.02 (t test)
extensively studied in neuroblastoma, and a complex expres-
sion proﬁle showing variations between neuroblastoma
tumors with diﬀerent malignant potential was described
[31]. Moreover, patterns of ganglioside expression were used
as indicators to predict patient outcome as a prognostic
indicator [31].
The overexpression of GD2 has been widely reported
in neuroblastoma. It is expressed in virtually all cases,
and it has been used as a target for immunotherapy after
the development of anti-GD2 speciﬁc antibodies. The use
of anti-GD2 murine or humanized antibodies for passive
immunotherapy has shown to be an eﬀective treatment of
MRD, as reported by randomized studies [6]. However, this
treatment requires frequent intravenous injections, and it
may be associated to severe toxicity such as hypersensitivity
reactions and capillary leak syndrome appearing in up to
25% of the cases. In addition, this treatment is only available
for use within clinical trials in Europe and the USA, so it is
currently not an option in less developed countries. In these
settings, current therapies with high dose chemotherapy
and autologous stem cell rescue are available, but novel
treatments for MRD are needed to improve outcome.
Based upon our present results, active immunother-
apy with the anti-idiotype vaccine racotumomab, targeting
NeuGc-containing gangliosides, may be feasible in children
with high-risk neuroblastoma. The wide expression of
NeuGc-GM3 and the favorable toxicity proﬁle of racotu-
momab [11–14] may make it an attractive option for clinical
use. Our results were used as background for launching
a Phase I evaluation of racotumomab in children with
neuroectodermal tumors in our hospital. However, theseClinical and Developmental Immunology 5
results should be considered preliminary since a more
detailed study on the expression of NeuGc-GM3 in diﬀerent
subsets of neuroblastoma is necessary. In addition, since
expression of this gangliosides by neuroblastoma cells may
be related to dietary uptake, diﬀerent expression patterns in
infants may be evident.
In our series, the use of preoperative chemotherapy
may have changed the histopathological appearance and
immunoreactivity. For instance, tumor cell subpopulations
expressing NeuGc-GM3 may not be easily detectable in
necrotic tumors after chemotherapy. As hypoxia-resistant
cancer cells are known to have diminished response to
chemotherapy, it is important to ﬁnd potential target
moleculesfornovelantitumorstrategies[32].Inthiscontext,
resistant cancer cells could overexpress NeuGc-containing
gangliosides under hypoxic conditions [33], but our study
was not designed to assess this phenomenon. The ability of
young children aﬀected with neuroblastoma to develop an
eﬀectiveimmuneresponsetoracotumomabvaccinationmay
be limited, and this is also a focus of our current research.
In contrast to GD2 that is normally expressed in neural
tissue of young children, NeuGc-containing gangliosides,
including NeuGc-GM3, are virtually absent in normal
human tissues, making these gangliosides immunogenic. In
fact, antibodies that recognize NeuGc residues appear after
administration of animal serum to humans [34]. Therefore,
NeuGc-targeted immunotherapy may be considered an
interesting candidate in neuroblastoma or other pediatric
tumors such as ESFT. Although the number of cases is
small, the present characterization of a speciﬁc neoantigen
in neuroectodermal tumors may be of value for the design of
immunotherapeutic protocols.
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